

ALCON AG

ISIN: CH0432492467

WKN: H01301128

Asset Class: **Stock**

Company

2024/05/03 21:04:43

Alcon

Price

79.60

USD

Difference



1.50%(1.18)

Contact Details

ALCON AG

Tel: +41-817-293-04-50

--

Fax:

+41-817-916-26-52

Royce Bedward, Chemin de
Blandonnet 8
1214 Genf

Web:

<http://www.alcon.com>

E-mail: -



Company Profile

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	4,752,797,000		4,804,563,000		4,907,453,000	
Common stock capital		16,833,000		18,504,000		18,223,000
Fixed assets	20,171,825,000		22,219,603,000		20,603,834,000	
Equity capital of a company		17,358,189,000		18,205,160,000		17,545,104,000
Cash and cash equivalents	920,765,000		906,696,000		1,435,061,000	
Accrued liabilities		520,139,000		514,411,000		703,407,000
Other assets	-		-		-	
Current liabilities		2,087,292,000		2,573,906,000		2,252,362,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		5,479,141,000		6,245,100,000		5,713,821,000
Different income		-		-		-
Other liabilities		139,713,000		212,796,000		153,073,000
Total assets	24,924,623,000	24,924,623,000	27,024,166,000	27,024,166,000	25,511,288,000	25,511,288,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	25,315	25,178	24,389
Equity ratio	69.64%	67.37%	68.77%
Debt-equity ratio	43.59%	48.44%	45.40%

Others

	2023	2022	2021
Tax Expense Rate	-17.07%	27.65%	10.05%

Income statement

	2023	2022	2021
Turnover	8,496,752,000	8,325,302,000	7,580,182,000
Net income	875,286,000	319,946,000	343,764,000
EBIT	894,187,249	565,713,243	498,670,613
Operating income before taxes	747,678,000	442,195,000	382,163,000
Cash Flow	1,247,328,000	1,162,314,000	1,229,688,000
Net interest income	-129,405,000	-112,697,000	-106,969,000
Research and development expenses	744,083,000	670,455,000	597,015,000
Income taxes	-127,608,000	122,248,000	38,399,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	342,186	337,106	316,864

Board of Directors

Arthur Cummings	Member of the administrative board
Bono Raquel Cruz	Member of the administrative board
Dieter Spälti	Member of the administrative board
D. Grossman	Member of the administrative board
Ines Pöschel	Member of the administrative board
Karen May	Member of the administrative board
Lynn Bleil	Member of the administrative board
Scott Maw	Member of the administrative board
Thomas Heinrich Glanzmann	Member of the administrative board
F. Ball	Chairman of the administrative board

Members of Management Board

David J. Endicott	Chairman of Managing Board
Ian Bell	Member of Executive Committee
Laurent Attias	Member of Executive Committee
Rajkumar Narayanan	Member of Executive Committee
Sergio Duplan	Member of Executive Committee
Sue-Jean Lin	Member of Executive Committee
Tim Stonesifer	Member of Executive Committee